Insider Selling: Davita Inc (DVA) Insider Sells 7,048 Shares of Stock
Davita Inc (NYSE:DVA) insider Charles Berg sold 7,048 shares of the stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $69.24, for a total value of $488,003.52. Following the sale, the insider now directly owns 5,359 shares of the company’s stock, valued at $371,057.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Davita Inc (DVA) traded up $0.90 on Wednesday, hitting $71.30. The company had a trading volume of 2,478,713 shares, compared to its average volume of 1,664,529. The company has a quick ratio of 1.35, a current ratio of 1.40 and a debt-to-equity ratio of 1.79. Davita Inc has a one year low of $52.51 and a one year high of $71.44. The stock has a market capitalization of $13,070.00, a P/E ratio of 19.86, a price-to-earnings-growth ratio of 14.01 and a beta of 0.97.
Davita (NYSE:DVA) last released its earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.94 by ($0.13). Davita had a return on equity of 13.31% and a net margin of 3.40%. The firm had revenue of $3.92 billion during the quarter, compared to analysts’ expectations of $3.91 billion. During the same period in the prior year, the business earned $0.95 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. sell-side analysts anticipate that Davita Inc will post 3.42 EPS for the current year.
Large investors have recently added to or reduced their stakes in the business. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Davita in the third quarter worth $154,000. Pzena Investment Management LLC increased its position in Davita by 2.1% in the second quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock worth $220,000 after buying an additional 71 shares during the last quarter. Eqis Capital Management Inc. increased its position in Davita by 62.5% in the third quarter. Eqis Capital Management Inc. now owns 7,473 shares of the company’s stock worth $444,000 after buying an additional 2,873 shares during the last quarter. Jensen Investment Management Inc. increased its position in Davita by 24.2% in the second quarter. Jensen Investment Management Inc. now owns 9,740 shares of the company’s stock worth $631,000 after buying an additional 1,900 shares during the last quarter. Finally, Accident Compensation Corp increased its position in Davita by 147.5% in the second quarter. Accident Compensation Corp now owns 15,100 shares of the company’s stock worth $978,000 after buying an additional 9,000 shares during the last quarter. 85.32% of the stock is owned by institutional investors and hedge funds.
A number of analysts recently commented on DVA shares. Royal Bank of Canada reaffirmed a “hold” rating and set a $64.00 price target on shares of Davita in a research report on Wednesday, September 6th. J P Morgan Chase & Co downgraded Davita from a “neutral” rating to an “underweight” rating in a research report on Monday, October 9th. KeyCorp reaffirmed a “hold” rating on shares of Davita in a research report on Tuesday, October 10th. Zacks Investment Research downgraded Davita from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, SunTrust Banks set a $57.00 price target on Davita and gave the company a “hold” rating in a research report on Sunday, October 15th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating, three have given a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $73.33.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.